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Abstract
Background: Upper gastrointestinal (GI) symptoms such as nausea and vomiting are common
adverse events associated with selective serotonin reuptake inhibitors (SSRIs), and may result in
discontinuation of drug therapy in patients with depressive disorder. Rikkunshi-to (formulation TJ-
43), a traditional herbal medicine, has been reported to improve upper GI symptoms and comorbid
depressive symptoms in patients with functional dyspepsia. The aim of the present study was to
determine if TJ-43 reduces GI symptoms and potentiates an antidepressant effect in a randomized
controlled study of depressed patients treated with fluvoxamine (FLV).
Methods: Fifty patients with depressive disorder (19–78 years, mean age 40.2 years) were treated
with FLV (n = 25) or FLV in combination with TJ-43 (FLV+TJ-43) (n = 25) for eight weeks. The
following parameters of the two groups were compared: The number of patients who complained
of adverse events and their symptoms; GI symptoms quality of life (QOL) score, assessed by the
Gastrointestinal Symptom Rating Scale (GSRS), Japanese edition, before and two weeks after
beginning treatment; and depressive symptoms assessed by the Self-Rating Depression Scale (SDS),
before and 2, 4, and 8 weeks after beginning treatment.
Results: The number of patients who complained of adverse events in the FLV+TJ-43 group (n =
6) was significantly lower than the number complaining in the FLV group (n = 13) (P < 0.05). The
number of patients who complained of nausea was also lower in the FLV+TJ-43 group (n = 3) than
in the FLV group (n = 9) (P < 0.05). By two weeks after treatment, GSRS scores had improved in
the FLV+TJ-43 group, but not in the FLV group. SDS scores were not different between the two
groups at any of the assessment points.
Conclusion: This study suggests that Rikkunshi-to reduces FLV-induced adverse events, especially
nausea, and improves QOL related to GI symptoms without affecting the antidepressant effect of
FLV.
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Background
Upper gastrointestinal (GI) symptoms such as nausea and
vomiting are one of the most common adverse events
caused by selective serotonin reuptake inhibitors (SSRIs)
[1-6]. In some patients, upper GI symptoms are critical
issues that impair their quality of life (QOL) and may
result in discontinuation of SSRI therapy.
Rikkunshi-to is a traditional Japanese herbal (Kampo)
medicine for treating upper GI tract symptoms such as
nausea, indigestion, and anorexia. Rikkunshi-to Extract
Granules for Ethical Use (Tsumura and Co., Product
number TJ-43) (7.5 g), containing 4.0 g of dried extract
obtained from mixed raw herbs in the following ratio: JP
Atractylodes Lancea Rhizome, 4.0 g; JP Ginseng, 4.0 g; JP
Pinellia Tuber, 4.0 g; JP Poria Sclerotium, 4.0 g; JP Jujube,
2.0 g; JP Citrus Unshiu Peel, 2.0 g; JP Glycyrrhiza, 1.0 g;
and JP Ginger,0.5 g; has been approved for medicinal use
by the Japanese Ministry of Health and Welfare. Today in
Japan, Rikkunshi-to is widely used for treating the upper
GI symptoms of patients with functional dyspepsia (FD)
[7,8] and gastroesophageal reflux [9], dyspeptic symp-
toms of postgastrointestinal surgery patients [10], and
chemotherapy-induced nausea in breast cancer patients
[11]. Rikkunshi-to has also been reported to improve
depressive symptoms and high cortisolemia in depressed
FD patients [12,13].
We therefore hypothesized that Rikkunshi-to might atten-
uate SSRI-induced GI symptoms and potentiate the anti-
depressant effect of SSRIs. To test this hypothesis, a
randomized controlled study was done in which we
treated depressed patients with fluvoxamine maleate
(FLV) with or without Rikkunshi-to, and compared the
rates of adverse reactions of the two groups, focusing on
GI symptoms and changes in self-rating depression scores.
Subjects and methods
Subjects
This study was approved by the Ethics Committee of the
University of Occupational and Environmental Health,
Japan, and conducted in accordance with its guidelines.
Fifty patients with depressive disorders were randomly
assigned to one of the following groups: FLV group (n =
25) or FLV plus Rikkunshi-to (FLV+TJ-43) group (n = 25).
The subjects were treated with either FLV or FLV plus TJ-43
for eight weeks. They were all diagnosed according to the
Diagnostic and Statistical Manual of Mental Disorders IV
as having depressive disorders, including major and
minor depressive disorders. In both groups, the initial
daily dose of FLV was 50 mg, and the dose was increased
weekly up to 150 mg. The dose of FLV was adjusted in
accordance with a patient's adverse reactions or at their
request. Therefore, the final maximal dose in some
patients was less than 150 mg. The FLV+TJ-43 group
received a granular extract of Rikkunshi-to (TJ-43,
Tsumura and Co., Tokyo, Japan) at a daily dose of 7.5 g
(2.5 g orally, three times per day). Subjects who had taken
any antidepressants, prokinetics, or herbal medicines
were excluded from this study. However, subjects who
were taking hypnotics or benzodiazepines regularly for
more than two weeks before the study were included, and
the doses of those drugs were not changed during the
investigation period.
Some patients complained of GI symptoms as well as
depressed mood before the start of the treatment. These
cases underwent an upper GI endoscopy, colorectal
endoscopy, or ultrasonography to confirm that there were
no organic diseases accounting for their GI symptoms.
Patients in whom organic diseases such as gastric ulcer
were found were excluded from this study even though
they were depressed. Patients complaining of severe GI
symptoms who asked for symptomatic treatment as well
as antidepressants were excluded from this study, even if
there were no organic lesions detected and they had been
diagnosed with a depressive disorder. The only subjects
enrolled in this study were those whose GI symptoms
were not so severe that they required symptomatic relief
before the start of the treatment.
Assessment
The following parameters were compared between the
FLV group and the FLV+TJ-43 group: (1) the number of
patients who complained of adverse events and their
symptoms; (2) GI symptoms specific QOL score accord-
ing to the Gastrointestinal Symptom Rating Scale (GSRS),
Japanese edition [14]; and (3) depressive symptoms
according to the Self-rating Depression Scale (SDS), Japa-
nese edition [15,16]. The GSRS scores were also compared
in each group between the pretreatment and posttreat-
ment periods.
Adverse events were checked during interviews by physi-
cians at every patient visit, which took place before and 1,
2, 4, 6, and 8 weeks after the start of the treatment.
Patients were also instructed to call their physicians if they
experienced adverse events, because previous studies have
demonstrated that FLV-induced adverse events occur
within one or several days after taking FLV. In this study,
we listed the symptoms as adverse events if the patient
described them as adverse events. As described in the
Results, a considerable number of patients had GI symp-
toms before the start of the treatment. Therefore, if
patients found it difficult to distinguish GI adverse events
from daily fluctuations of depression-related GI symp-
toms, those events were not listed as adverse. Whenever
subjects complained of adverse events and asked for alle-
viation of their symptoms, they were treated symptomati-BioPsychoSocial Medicine 2007, 1:21 http://www.bpsmedicine.com/content/1/1/21
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cally with antiemetic drugs or laxatives. Patients
requesting symptomatic relief during an evaluation visit
were excluded from GSRS and SDS assessments after that
visit.
The GSRS is a self-administered questionnaire for assess-
ing GI symptoms, and consists of 15 items [14,17,18].
These include five subscales for reflux, abdominal pain,
indigestion, diarrhea, and constipation. The higher the
scores, the more pronounced the symptoms. GSRS total
scores and the five subscale scores were compared before
and 15 days after beginning treatment in patients who
were able to take FLV continuously for two weeks without
asking for any medications to treat adverse events. GSRS
was not assessed two weeks after treatment in those who
complained of GI adverse events if they had already
stopped taking FLV or FLV+TJ-43, or if they had already
been treated symptomatically before the post-treatment
GSRS assessment.
SDS scores between the FLV group and the FLV+TJ-43
group were compared at time points before and 2, 4, and
8 weeks after treatment.
Statistical analyses
The Student t-test for unmatched data, Welch t test, and
Mann-Whitney U test were used. The Fisher exact proba-
bility test was also used when appropriate.
The paired t test was used to compare GSRS scores before
and after treatment. Statistical significance was considered
to be P < 0.05.
Results
Demographic and baseline characteristics
There were no differences in the demographic and base-
line characteristics between the FLV and the FLV+TJ-43
groups for age, sex, GSRS total and five subscale scores,
and SDS score (Table 1). Upper GI symptoms seen before
the start of the treatment were epigastral discomfort (8
patients in the FLV group vs. 10 patients in the FLV+TJ-43
group), nausea (7 patients vs. 11 patients, respectively)
and abdominal fullness (5 patients vs. 4 patients, respec-
tively). There were no between group differences in the
incidence of GI symptoms or the administered dose of
FLV at any time point (Table 2).
Adverse events
13 out of 25 patients (52%) in the FLV group and 6 out of
25 patients (24%) in the FLV+TJ-43 group complained of
adverse events. The incidence of adverse events in the
FLV+TJ-43 group was significantly lower than in the FLV
group (P < 0.05, Fig. 1). Adverse reactions are listed in
Table 3. In the FLV group, the percentages of patients com-
plaining of GI symptoms that were considered adverse
events, were nausea, 36%; anorexia, 12%; abdominal full-
ness, 4%; constipation, 4%; and diarrhea, 4%. In the
FLV+TJ-43 group, the percentages of subjects complaining
of symptoms considered adverse events were nausea,
12%, and anorexia, 12%. The number of subjects who
complained of nausea in the FLV+TJ-43 group was signif-
icantly lower than in the FLV group (P < 0.05, Table 3). As
previously described, only the symptoms described by
patients as not being daily fluctuations of depression-
related GI symptoms were listed as adverse events (Table
3). Patients did not seem to have difficulty in distinguish-
ing between adverse events and daily fluctuations,
because there were differences in severity and the time of
occurrence of symptoms, e.g. more severe nausea than
usual occurring within several hours after taking the first
FLV tablet. In both groups, most adverse events appeared
just after beginning treatment or within several days after
increasing the dose of FLV. They appeared 1–15 days (7.9
± 4.9 days, mean ± SD) after beginning treatment in the
Table 2: Mean dose of FLV.
Time FLV (n) FLV+TJ-43 (n)
1st week 48.9 ± 5.1 (25) 48.0 ± 6.9 (25) n.s.
2nd week 85.3 ± 22.6 (19) 92.1 ± 18.7 (19) n.s.
4th week 125.0 ± 35.0 (13) 134.2 ± 33.5 (19) n.s.
8th week 129.2 ± 32.5 (13) 136.1 ± 33.5 (19) n.s.
In parentheses, number of patients is indicated. FLV = fluvoxamine; TJ-43 = Rikkunshito. mean ± SD. N.s. = not significant. Student t-test for 
unmatched data.
Table 1: Patient characteristics of the treatment groups.
Variable FLV FLV+TJ-43
Number 25 25
Age, years 40.3 ± 17.3 40.2 ± 16.1 n.s.1)
Sex
Male 18 (72%) 18 (72%)
Female 7 (28%) 7 (28%) n.s.2)
GSRS total score 2.30 ± 1.18 2.53 ± 1.03 n.s.3)
SDS score 56.0 ± 7.0 56.6 ± 7.8 n.s.1)
FLV = fluvoxamine; TJ-43 = Rikkunshito; GSRS = gastrointestinal 
symptom rating scale; SDS = self-rating depression scale. mean ± SD. 
N.s. = not significant.
1) Student t-test for unmatched data. 2) Fisher exact probability test. 
3) Student t-test for unmatched data and Mann-Whitney U test.BioPsychoSocial Medicine 2007, 1:21 http://www.bpsmedicine.com/content/1/1/21
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FLV group and 1–8 days (5.6 ± 2.6 days) after beginning
treatment in the FLV+TJ-43 group. Because of adverse
reactions, 12 subjects in the FLV group and 6 subjects in
the FLV+TJ-43 group asked for medication or stopped tak-
ing FLV during the investigation period. One subject in
the FLV group complained of discomfort one week after
beginning FLV (50 mg), but asked to continue the FLV
therapy. This patient was treated with FLV for eight weeks
without increasing the dose.
GI symptoms
The GSRS total and five subscale scores were compared
between the FLV group and the FLV+TJ-43 group at pre-
treatment (Table 4). There were no between group differ-
ences in any of the GSRS scores at baseline. The
pretreatment scores and 15 day scores were then com-
pared for those who took FLV or FLV+TJ-43 continuously
for two weeks. In the FLV group (n = 15), there were no
differences in the means of the GSRS total and five sub-
scale scores between the pretreatment and posttreatment
periods. In the FLV+TJ-43 group (n = 19), the mean of the
GSRS total scores significantly improved from 2.45 to
1.97 (P < 0.05). Among the five subscale scores, the mean
GSRS abdominal pain score showed a tendency to
improve, from 3.03 to 2.18, and the mean GSRS diarrhea
symptom score showed a tendency to improve, from 2.25
to 1.65, following treatment.
Depressive symptoms
SDS scores were compared between the FLV group and the
FLV+TJ-43 group before and 2, 4, and 8 weeks after the
start of treatment. There were no between group differ-
ences in the SDS scores at any time point (Fig. 2).
Although the mean SDS scores four weeks after the begin-
ning of treatment were 53.1 in the FLV group (n = 13) and
47.8 in the FLV+TJ-43 group (n = 19), the difference was
not statistically significant.
Discussion
This study demonstrates that the number of subjects who
reported adverse events was significantly lower in the
FLV+TJ-43 group than in the FLV group, suggesting that
Table 4: Changes in GSRS scores by FLV and FLV+TJ-43 
treatment.
GSRS score pre-treatment post-treatment
Total
FLV 2.42 ± 1.24 2.52 ± 0.99 n.s.
FLV+TJ-43 2.45 ± 1.10 1.97 ± 0.81 *
Reflux
FLV 2.13 ± 1.46 2.50 ± 1.35 n.s.
FLV+TJ-43 2.37 ± 1.61 2.00 ± 0.91 n.s.
Abdominal pain
FLV 2.63 ± 1.56 3.18 ± 1.81 n.s.
FLV+TJ-43 3.03 ± 1.82 2.18 ± 1.00 +
Indigestion
FLV 1.70 ± 0.97 1.87 ± 0.74 n.s.
FLV+TJ-43 2.05 ± 0.95 1.78 ± 1.06 n.s.
Diarrhea
FLV 2.87 ± 1.78 2.35 ± 1.60 n.s.
FLV+TJ-43 2.25 ± 1.47 1.65 ± 1.06 +
Constipation
FLV 2.64 ± 1.87 2.83 ± 1.33 n.s.
FLV+TJ-43 2.66 ± 1.69 2.34 ± 1.53 n.s.
FLV = fluvoxamine; TJ-43 = Rikkunshito. mean ± SD. * p < 0.05, + p < 
0.1 by paired t-test.
The number of patients who complained of adverse events Figure 1
The number of patients who complained of adverse events. 
Percentage is shown in parentheses. *P < 0.05 by the Fisher 
exact probability test. FLV = fluvoxamine; TJ-43 = Rikkunshi-
to. The number (%) is shown in the column.
Table 3: Adverse events associated with FLV and FLV+TJ-43 
treatment.
FLV FLV+TJ-43
Adverse events Number (%) of patients reporting event
GI symptoms
Nausea 9 (36) center3 (12) *
Anorexia 3 (12) 3 (12)
Abdominal fullness 1 (4) 0 (0)
Constipation 1 (4) 0 (0)
Diarrhea 1 (4) 0 (0)
Feel discomfort 3 (12) 2 (8)
Feel irritable 1 (4) 0 (0)
Difficulty in urinating 1 (4) 0 (0)
General fatigue 1 (4) 0 (0)
Tremor 0 (0) 1 (4)
/25 /25
FLV = fluvoxamine; TJ-43 = Rikkunshito; GI:gastrointestinal. * p < 0.05 
by Fisher exact probability test.BioPsychoSocial Medicine 2007, 1:21 http://www.bpsmedicine.com/content/1/1/21
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Rikkunshi-to attenuates SSRI-induced adverse reactions.
In the present study, 52% of the patients who took FLV
complained of one or more adverse events. This incidence
is similar to those seen in previous clinical trials con-
ducted in Japan, in which 47–51% of subjects reported
adverse events when they took FLV at 90–150 mg daily [2-
4]. By contrast, only 24% of patients in the FLV+TJ-43
group complained of adverse events. Nausea was the most
common adverse event of FLV, and 10–37% of subjects
who took FLV reported nausea in previous studies [2-6].
In this study, 36% of the patients in the FLV group com-
plained of nausea, contrasting with only 12% of the
patients in the FLV+TJ-43 group who complained of nau-
sea, a significantly lower incidence. Rikkunshi-to also has
been reported to have adverse reactions. Typical adverse
events of Rikkunshi-to are diarrhea and edema. Previously
reported incidences of diarrhea and edema were 0–2.3%
and 0–6.7%, respectively [7,8,12]. In this study, no
patient in the FLV+TH-43 group reported diarrhea or had
edema. Therefore, Rikkunshi-to may reduce the incidence
of FLV-induced nausea without causing the reported
adverse reactions.
Rikkunshi-to is a traditional herbal (Kampo) prescrip-
tions approved by Japanese National Health Insurance for
medicinal use (for review, see [19]). It has been widely
prescribed to treat upper GI symptoms in patients with FD
[7,8,12], gastroesophageal reflux [9], dyspeptic symptoms
of children after surgery [10], and chemotherapy-induced
nausea in breast cancer patients [11]. A double-blind, ran-
domized, controlled study has demonstrated the useful-
ness of Rikkunshi-to for FD [8]. Another study
demonstrated that Rikkunshi-to is more effective than the
prokinetic drug, cisapride [7]. The present study suggested
that Rikkunshi-to is also effective for SSRI-induced nau-
sea.
Rikkunshi-to is well known for improving dysfunction in
gastric motility, which may cause upper GI tract symp-
toms. It has been demonstrated to promote gastric adap-
tive relaxation in isolated guinea pig stomachs [20], and
to facilitate delayed gastric emptying in rats [21] and in FD
patients [22,23]. Rikkunshi-to has also been demon-
strated to prevent intracellular signaling disorders in the
gastric smooth muscle of diabetic rats [24].
The precise mechanisms of FLV-induced nausea remain
uncertain. However, stimulation of serotonin (5-HT)3
receptors in the enteric nervous system or within the brain
may cause SSRI-induced nausea, because 5-HT3 receptor
antagonists such as ondansetron [25] and cisapride [26]
have been reported to attenuate SSRI-induced nausea.
Furthermore, it is suggested that FLV-induced nausea is
associated with serotonergic neuronal hyperactivity in the
GI tract [6]. Thus far it is not known if Rikkunshi-to affects
serotonergic systems in the enteric nervous system or
within the brain; however, the effects of Rikkunshi-to on
gastric function may be attributed, at least in part, to its
inhibitory effect on SSRI-induced GI symptoms and its
alleviation of GI tract symptoms related to QOL.
We previously demonstrated that administration of
Rikkunshi-to for four weeks decreased depressive symp-
toms in FD patients, especially general fatigue, depressed
mood, and loss of taste [12]. Therefore, we were very inter-
ested in seeing if Rikkunshi-to could potentiate the anti-
depressant effect of FLV. There were no differences in the
mean SDS scores between the FLV and FLV+TJ-43 groups
at two and eight weeks. The mean SDS scores at four
weeks were lower in the FLV+TJ-43 group than in the FLV
group; however, the difference was not statistically signif-
icant. These results may be partly because of the relatively
small number of subjects studied. Therefore, an addi-
tional larger study is required to determine if Rikkunshi-
to really exhibits an additive antidepressant effect in addi-
tion to FLV. However, from a different perspective, this
study clearly showed that Rikkunshi-to does not inhibit
the antidepressant effect of FLV.
Also limiting the study is that it was conducted by com-
paring effects seen in an FLV group and an FLV+TJ-43
group. To avoid bias, however, comparisons might better
have been made between an FLV+placebo group and an
FLV+TJ-43 group.
Conclusion
This study suggests that Rikkunshi-to attenuates SSRI-
induced nausea and improves QOL related to GI symp-
Changes in SDS scores Figure 2
Changes in SDS scores. FLV = fluvoxamine; TJ-43 = Rikkun-
shi-to. Not significant at any time point by Student t-test for 
unmatched data, Welch t test, and Mann-Whitney U tests.BioPsychoSocial Medicine 2007, 1:21 http://www.bpsmedicine.com/content/1/1/21
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toms, without affecting the antidepressant effect of fluvox-
amine.
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